James Goya Heaf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8959786/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrology Dialysis Transplantation, 2002, 17, 112-117.	0.7	324
2	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survivalan analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.7	180
3	An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006. Nephrology Dialysis Transplantation, 2009, 24, 3557-3566.	0.7	129
4	The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2016, 31, 831-841.	0.7	125
5	The epidemiology and prognosis of glomerulonephritis in Denmark 1985–1997. Nephrology Dialysis Transplantation, 1999, 14, 1889-1897.	0.7	112
6	Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. CKJ: Clinical Kidney Journal, 2015, 8, 248-261.	2.9	97
7	Bone disease after renal transplantation. Transplantation, 2003, 75, 315-325.	1.0	92
8	Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrology Dialysis Transplantation, 2015, 30, 1028-1037.	0.7	81
9	Relative Survival of Peritoneal Dialysis and Haemodialysis Patients: Effect of Cohort and Mode of Dialysis Initiation. PLoS ONE, 2014, 9, e90119.	2.5	76
10	Hyperparathyroidism and longâ€ŧerm bone loss after renal transplantation. Clinical Transplantation, 2003, 17, 268-274.	1.6	74
11	Renal replacement therapy in Europe: a summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. CKJ: Clinical Kidney Journal, 2016, 9, 457-469.	2.9	70
12	Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrology Dialysis Transplantation, 2014, 29, 1284-1300.	0.7	69
13	Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv1-iv8.	0.7	65
14	The origin of the 1·73-m2body surface area normalization: problems and implications. Clinical Physiology and Functional Imaging, 2007, 27, 135-137.	1.2	52
15	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association–European Dialysis and Transplant Association Registry. American Journal of Kidney Diseases. 2015. 66. 613-620.	1.9	52
16	Dialysis modality choice in diabetic patients with end-stage kidney disease: a systematic review of the available evidence. Nephrology Dialysis Transplantation, 2015, 30, 310-320.	0.7	47
17	Dietary habits and nutritional status of renal transplant patients. , 2004, 14, 20-25.		39
18	Dialysis modality choice in elderly patients with end-stage renal disease: a narrative review of the available evidence: TableÂ1 Nephrology Dialysis Transplantation, 2017, 32, gfv411.	0.7	37

James Goya Heaf

#	Article	IF	CITATIONS
19	Renal replacement therapy in Europe: a summary of the 2011 ERA-EDTA Registry Annual Report. CKJ: Clinical Kidney Journal, 2014, 7, 227-238.	2.9	35
20	Metformin in Chronic Kidney Disease: Time for a Rethink. Peritoneal Dialysis International, 2014, 34, 353-357.	2.3	35
21	Causes and Consequences of Adynamic Bone Disease. Nephron, 2001, 88, 97-106.	1.8	34
22	Current trends in European renal epidemiology. CKJ: Clinical Kidney Journal, 2017, 10, 149-153.	2.9	31
23	Quantification of cancer risk in glomerulonephritis. BMC Nephrology, 2018, 19, 27.	1.8	30
24	The Danish Renal Biopsy Register. Kidney International, 2004, 66, 895-897.	5.2	27
25	Comparison of Dual Energy X-ray Absorptiometry and Bioimpedance in Assessing Body Composition and Nutrition in Peritoneal Dialysis Patients. , 2017, 27, 355-363.		26
26	Kidney Versus Combined Kidney and Liver Transplantation in Young People With Autosomal Recessive Polycystic Kidney Disease: Data From the European Society for Pediatric Nephrology/European Renal Associationâ^`European Dialysis and Transplant (ESPN/ERA-EDTA) Registry. American Journal of Kidney Diseases, 2016, 68, 782-788.	1.9	25
27	Treatment and Prognosis of Extracapillary Glomerulonephritis. Nephron, 1983, 35, 217-224.	1.8	20
28	Non-medical barriers reported by nephrologists when providing renal replacement therapy or comprehensive conservative management to end-stage kidney disease patients: a systematic review. Nephrology Dialysis Transplantation, 2021, 36, 848-862.	0.7	20
29	Kidney transplant outcomes from older deceased donors: a paired kidney analysis by the European Renal Association-European Dialysis and Transplant Association Registry. Transplant International, 2018, 31, 708-719.	1.6	17
30	Pathogenic Effects of a High Peritoneal Transport Rate. Seminars in Dialysis, 2001, 13, 188-193.	1.3	14
31	Renal replacement therapy in Europe—a summary of the 2010 ERA–EDTA Registry Annual Report. CKJ: Clinical Kidney Journal, 2013, 6, 105-115.	2.9	14
32	The Danish Nephrology Registry. Clinical Epidemiology, 2016, Volume 8, 621-627.	3.0	14
33	Long-term haemodialysis survival. CKJ: Clinical Kidney Journal, 2012, 5, 168-169.	2.9	12
34	Reduced incidence of end stage renal disease among the elderly in Denmark: an observational study. BMC Nephrology, 2012, 13, 131.	1.8	12
35	Vitamin D and Stage 5 Chronic Kidney Disease: A New Paradigm?. Seminars in Dialysis, 2012, 25, 50-58.	1.3	12
36	Home hemodialysis: Infrastructure, water, and machines in the home. Hemodialysis International, 2015, 19, S93-S111.	0.9	11

James Goya Heaf

#	Article	IF	CITATIONS
37	Choice of dialysis modality among patients initiating dialysis: results of the Peridialysis study. CKJ: Clinical Kidney Journal, 2021, 14, 2064-2074.	2.9	11
38	Uraemia Progression in Chronic Kidney Disease Stages 3–5 Is Not Constant. Nephron Clinical Practice, 2011, 118, c367-c374.	2.3	10
39	Peritoneal transport: getting more complicated. Nephrology Dialysis Transplantation, 2012, 27, 4248-4251.	0.7	10
40	Why do physicians prescribe dialysis? A prospective questionnaire study. PLoS ONE, 2017, 12, e0188309.	2.5	10
41	Protein-bound solute removal during extended multipass versus standard hemodialysis. BMC Nephrology, 2015, 16, 57.	1.8	9
42	Chronic KidneY Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient. Peritoneal Dialysis International, 2015, 35, 640-644.	2.3	9
43	Suboptimal dialysis initiation is associated with comorbidities and uraemia progression rate but not with estimated glomerular filtration rate. CKJ: Clinical Kidney Journal, 2021, 14, 933-942.	2.9	9
44	Increased incidence and improved prognosis of glomerulonephritis: a national 30-year study. CKJ: Clinical Kidney Journal, 2021, 14, 1594-1602.	2.9	9
45	Multipass haemodialysis: a novel dialysis modality. Nephrology Dialysis Transplantation, 2013, 28, 1255-1264.	0.7	8
46	Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients. CKJ: Clinical Kidney Journal, 2009, 2, 267-272.	2.9	7
47	Differences in survival on chronic dialysis treatment between ethnic groups in Denmark: a population-wide, national cohort study. Nephrology Dialysis Transplantation, 2016, 31, 1160-1167.	0.7	6
48	Increased technetiumâ€99Âm hydroxy diphosphonate soft tissue uptake on bone scintigraphy in chronic kidney disease patients with secondary hyperparathyroidism: correlation with hyperphosphataemia. Clinical Physiology and Functional Imaging, 2017, 37, 131-136.	1.2	6
49	First-year mortality in incident dialysis patients: results of the Peridialysis study. BMC Nephrology, 2022, 23, .	1.8	6
50	Calculating the Rate of Senescence From Mortality Data: An Analysis of Data From the ERA-EDTA Registry. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 468-474.	3.6	5
51	Hypertensive nephropathy is associated with an increased risk of myeloma, skin, and renal cancer. Journal of Clinical Hypertension, 2019, 21, 786-791.	2.0	5
52	Mesangioproliferative Glomerulonephritis: A 30-Year Prognosis Study. Nephron Extra, 2014, 4, 26-32.	1.1	4
53	Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients aged 20–50 years: a study by the ERA–EDTA Registry. Nephrology Dialysis Transplantation, 2020, 35, 534-543.	0.7	4
54	The association of living donor source with patient and graft survival among kidney transplant recipients in the ERAâ€EDTA Registry – a retrospective study. Transplant International, 2021, 34, 76-86.	1.6	2

#	Article	IF	CITATIONS
55	Stable incidence and survival of arteriovenous fistulas over 39 years: A long-term national cohort study. Journal of Vascular Access, 2021, , 112972982110461.	0.9	1
56	The ratio of measured to estimated glomerular filtration rate may be a marker of early mortality and dialysis requirement. BMC Nephrology, 2021, 22, 370.	1.8	1